share_log

BRIEF-Vertex Announces FDA Fast Track Designation For VX-880

路透社 ·  Mar 10, 2021 20:56
March 10 (Reuters) - Vertex Pharmaceuticals Inc :
   * VERTEX ANNOUNCES FDA FAST TRACK DESIGNATION AND INITIATION OF A PHASE 1/2 CLINICAL TRIAL FOR VX-880, A NOVEL INVESTIGATIONAL CELL THERAPY FOR THE TREATMENT OF TYPE 1 DIABETES

Source text for Eikon:  Further company coverage:

((Reuters.Briefs@thomsonreuters.com;)
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment